Safety
anaemia, diarrhoea, decreased white blood cell count, neutropoenia, nausea, neutropenia, vomiting, rash, cough, dyspnoea, anorexia, shortness of breath
ADVERSE EVENTS, ANOREXIA, NEUTROPENIA, ANAEMIA
The population for safety comprised 37 patients who received erlotinib and 34 who received GC except for one patient who refused to receive chemotherapy after randomisation. The adverse events (AEs) of any grade occurred in 70.3% (26/37) of patients with erlotinib and 58.8% (20/34) with GC during postoperative therapy. In brief, the most common AEs were rash (43.2%), diarrhoea (24.3%) and cough (24.3%) in patients treated with erlotinib; and those in the GC group were neutropenia (38.2%), decreased white blood cell count (32.4%), anorexia (26.5%) and vomiting (26.5%). The grade 3 or 4 AEs occurred in 5 (13.5%) patients of the erlotinib group and in 10 (29.4%) patients of the GC group. The most common grade 3 or 4 AEs were rash (5.4%), diarrhoea (2.7%), shortness of breath (2.7%), elevated total bilirubin (2.7%), elevated aminotransferases (2.7%), and decreased white blood cell count (2.7%) in the erlotinib group. In the GC group, those were neutropoenia (29.4%), decreased white blood cell count (11.8%), vomiting (2.9%), nausea (2.9%), anaemia (2.9%) and dyspnoea (2.9%).